⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for waldenstrom's macroglobulinemia

Every month we try and update this database with for waldenstrom's macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Perifosine in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaNCT00422656
Waldenstrom's M...
Perifosine
18 Years - Dana-Farber Cancer Institute
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaNCT00265928
Lymphoma
bortezomib
rituximab
antibody therap...
biological ther...
enzyme inhibito...
monoclonal anti...
18 Years - National Cancer Institute (NCI)
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological MalignanciesNCT00150462
Waldenstrom's M...
Non-Hodgkin's L...
Hodgkin's Disea...
Multiple Myelom...
Carfilzomib
Dexamethasone
18 Years - Amgen
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaNCT02400437
Waldenstrom's M...
Ixazomib
Dexamethasone
Rituximab
18 Years - Dana-Farber Cancer Institute
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome SequencingNCT02604511
Waldenstrom's M...
Ibrutinib
18 Years - Dana-Farber Cancer Institute
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia'sNCT02371148
Waldenstrom's M...
Bortezomib-Ritu...
18 Years - Fondazione Italiana Linfomi - ETS
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersNCT01177527
Multiple Myelom...
Waldenstrom's M...
Smoldering Mult...
Lymphoblastic L...
18 Years - Dana-Farber Cancer Institute
Trial of AVN-944 in Patients With Advanced Hematologic MalignanciesNCT00273936
Acute Leukemia
Chronic Leukemi...
Multiple Myelom...
Hodgkin's Lymph...
Non-Hodgkin's L...
Waldenstrom's M...
AVN-944 capsule...
18 Years - Vertex Pharmaceuticals Incorporated
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodNCT00146055
Myeloma, Plasma...
Lymphoma, Malig...
Myeloproliferat...
Myelodysplastic...
Waldenstrom's M...
Reduced intensi...
- University of Michigan Rogel Cancer Center
Study of VTD in Waldenstrom's MacroglobulinemiaNCT03335098
Waldenstrom Mac...
Lymphoplasmacyt...
Bortezomib
19 Years - Seoul National University Hospital
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)NCT00422799
Waldenstrom's M...
Bortezomib
Rituximab
18 Years - Dana-Farber Cancer Institute
Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaNCT00142129
Waldenstrom's M...
Lymphoplasmacyt...
Bortezomib (Vel...
18 Years - 90 YearsDana-Farber Cancer Institute
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4NCT04274738
Waldenstrom's M...
Mavorixafor
Ibrutinib
18 Years - X4 Pharmaceuticals
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.NCT00919139
Multiple Myelom...
Smoldering Myel...
Waldenstrom's M...
Monoclonal Gamm...
Amyloidosis
biologic sample...
- SWOG Cancer Research Network
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT01647971
Non-Hodgkins Ly...
B-cell Lymphoma
Waldenstrom's M...
Marginal Zone L...
Chronic Lymphoc...
Small Lymphocyt...
Primary Central...
Ublituximab
18 Years - TG Therapeutics, Inc.
Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaNCT00142129
Waldenstrom's M...
Lymphoplasmacyt...
Bortezomib (Vel...
18 Years - 90 YearsDana-Farber Cancer Institute
Carfilzomib Plus Belinostat in Relapsed/Refractory NHLNCT02142530
Non-Hodgkin Lym...
Diffuse Large B...
Mantle Cell Lym...
Follicular Lymp...
Peripheral T-ce...
Carfilzomib
Belinostat
18 Years - Massachusetts General Hospital
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyNCT02381080
B-Cell Chronic ...
Ibrutinib
Erythromycin
Voriconazole
18 Years - Janssen Research & Development, LLC
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaNCT01125293
Waldenstrom's M...
Everolimus
Rituximab
Bortezomib
18 Years - Dana-Farber Cancer Institute
Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsNCT02071888
Non-Hodgkin's L...
Multiple Myelom...
Waldenstrom's M...
Other B-cell NH...
T-cell NHL
CB-839
CB-839 and low ...
CB-839, pomalid...
18 Years - Calithera Biosciences, Inc
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaNCT01046006
Waldenstrom's M...
Bortezomib, Rit...
18 Years - University of Athens
Study of MLN8237 in Participants With Advanced Hematological MalignanciesNCT00697346
B-cell Follicul...
B-cell Marginal...
Diffuse Large B...
B-cell Mantle C...
B-cell Small Ly...
B-Cell Chronic ...
Multiple Myelom...
Waldenstrom's M...
Noncutaneous Pe...
Angioimmunoblas...
Anaplastic Larg...
Enteropathy Ass...
NK Lymphoma
Alisertib
18 Years - Takeda
Ibrutinib (PCI-32765) in Waldenstrom's MacroglobulinemiaNCT01614821
Waldenstrom's M...
PCI-32765
18 Years - Dana-Farber Cancer Institute
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's MacroglobulinemiaNCT00936611
Waldenstrom's M...
LBH589
18 Years - Dana-Farber Cancer Institute
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodNCT00146055
Myeloma, Plasma...
Lymphoma, Malig...
Myeloproliferat...
Myelodysplastic...
Waldenstrom's M...
Reduced intensi...
- University of Michigan Rogel Cancer Center
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4NCT04274738
Waldenstrom's M...
Mavorixafor
Ibrutinib
18 Years - X4 Pharmaceuticals
Study of MLN8237 in Participants With Advanced Hematological MalignanciesNCT00697346
B-cell Follicul...
B-cell Marginal...
Diffuse Large B...
B-cell Mantle C...
B-cell Small Ly...
B-Cell Chronic ...
Multiple Myelom...
Waldenstrom's M...
Noncutaneous Pe...
Angioimmunoblas...
Anaplastic Larg...
Enteropathy Ass...
NK Lymphoma
Alisertib
18 Years - Takeda
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodNCT00146055
Myeloma, Plasma...
Lymphoma, Malig...
Myeloproliferat...
Myelodysplastic...
Waldenstrom's M...
Reduced intensi...
- University of Michigan Rogel Cancer Center
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's MacroglobulinemiaNCT00936611
Waldenstrom's M...
LBH589
18 Years - Dana-Farber Cancer Institute
Carfilzomib Plus Belinostat in Relapsed/Refractory NHLNCT02142530
Non-Hodgkin Lym...
Diffuse Large B...
Mantle Cell Lym...
Follicular Lymp...
Peripheral T-ce...
Carfilzomib
Belinostat
18 Years - Massachusetts General Hospital
Simvastatin in Waldenstrom's MacroglobulinemiaNCT00575965
Waldenstrom's M...
Simvastatin
18 Years - Dana-Farber Cancer Institute
Study of MLN8237 in Participants With Advanced Hematological MalignanciesNCT00697346
B-cell Follicul...
B-cell Marginal...
Diffuse Large B...
B-cell Mantle C...
B-cell Small Ly...
B-Cell Chronic ...
Multiple Myelom...
Waldenstrom's M...
Noncutaneous Pe...
Angioimmunoblas...
Anaplastic Larg...
Enteropathy Ass...
NK Lymphoma
Alisertib
18 Years - Takeda
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms MacroglobulinemiaNCT00250926
Waldenstrom's M...
Bortezomib
Dexamethasone
Rituximab
18 Years - Dana-Farber Cancer Institute
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's MacroglobulinemiaNCT00113802
Waldenstrom Mac...
Epratuzumab (hL...
18 Years - Gilead Sciences
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaNCT01470196
Waldenstrom's M...
Dexamethasone
Carfilzomib
Rituximab
18 Years - Dana-Farber Cancer Institute
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.NCT00919139
Multiple Myelom...
Smoldering Myel...
Waldenstrom's M...
Monoclonal Gamm...
Amyloidosis
biologic sample...
- SWOG Cancer Research Network
Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaNCT00142129
Waldenstrom's M...
Lymphoplasmacyt...
Bortezomib (Vel...
18 Years - 90 YearsDana-Farber Cancer Institute
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaNCT02439138
Waldenstrom's M...
GS-1101
18 Years - Dana-Farber Cancer Institute
Trial of AVN-944 in Patients With Advanced Hematologic MalignanciesNCT00273936
Acute Leukemia
Chronic Leukemi...
Multiple Myelom...
Hodgkin's Lymph...
Non-Hodgkin's L...
Waldenstrom's M...
AVN-944 capsule...
18 Years - Vertex Pharmaceuticals Incorporated
Study of VTD in Waldenstrom's MacroglobulinemiaNCT03335098
Waldenstrom Mac...
Lymphoplasmacyt...
Bortezomib
19 Years - Seoul National University Hospital
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaNCT01046006
Waldenstrom's M...
Bortezomib, Rit...
18 Years - University of Athens
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodNCT00146055
Myeloma, Plasma...
Lymphoma, Malig...
Myeloproliferat...
Myelodysplastic...
Waldenstrom's M...
Reduced intensi...
- University of Michigan Rogel Cancer Center
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's MacroglobulinemiaNCT02092909
Waldenstrom's M...
IMO-8400
18 Years - Idera Pharmaceuticals, Inc.
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersNCT01177527
Multiple Myelom...
Waldenstrom's M...
Smoldering Mult...
Lymphoblastic L...
18 Years - Dana-Farber Cancer Institute
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesNCT00807677
Acute Myeloid L...
Acute Lymphobla...
Chronic Myeloge...
Chronic Lymphoc...
Multiple Myelom...
Waldenstrom's M...
Myelodysplastic...
Philadelphia Ch...
Myeloid Metapla...
Myelofibrosis
Advanced Polycy...
Non-Hodgkins Ly...
TAK-901
18 Years - Millennium Pharmaceuticals, Inc.
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4NCT04274738
Waldenstrom's M...
Mavorixafor
Ibrutinib
18 Years - X4 Pharmaceuticals
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyNCT02381080
B-Cell Chronic ...
Ibrutinib
Erythromycin
Voriconazole
18 Years - Janssen Research & Development, LLC
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaNCT00081809
Lymphoma, Folli...
Lymphoma, Small...
autologous huma...
- Agenus Inc.
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabNCT00667329
Lymphoma
2CdA
Cyclophosphamid...
Rituximab
- M.D. Anderson Cancer Center
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabNCT00667329
Lymphoma
2CdA
Cyclophosphamid...
Rituximab
- M.D. Anderson Cancer Center
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaNCT01125293
Waldenstrom's M...
Everolimus
Rituximab
Bortezomib
18 Years - Dana-Farber Cancer Institute
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: